Our planet is facing a major pandemic outbreak due to COVID-19 and health agencies are taking every measure to stop it The outbreak of the respiratory disease was first detected in Wuhan City, Hubei Province, China in Dec 2019 PharmaShots is keeping a track of all of the important updates in the Lifesciences sector, where […]Read More
Shots: The P-III study involves assessing of PH94B vs PBO in 22 patients with Social Anxiety Disorder P-III study results: @1wk. decrease in average peak Subjective Units of Distress scores; decrease in Liebowitz Social Anxiety Scale (LSAS) avoidance scores; no Adverse Events; safety profile was excellent; Presented at Anxiety and Depression Association of America Annual […]Read More
Shots: Pherin will receive $2.25M of unregistered common stock (1,630,435 unregistered shares) from Vista VistaGen has rights to commercialize and develop PH94B nasal spray (expected to enter in P-III in H1’19) as a PRN treatment for SAD, in addition to an option to acquire Pherin’s CNS neuropsychiatry-focused product currently under P-II The main focus of […]Read More
Copyright ©2021 PharmaShots | Powered by Octavus Consulting
